Teladoc will spend more than $18 billion to buy digital health platform operator Livongo in a deal aimed at stoking explosive growth in remote care spurred by the pandemic.
The nation’s lone publicly traded telemedicine provider said Wednesday that it will pay a portion of its stock and $11.33 in cash for each Livongo share in deal it expects to close by the end of the year.
Millions of patients were forced to turn to telemedicine for everything from routine care to check ups with specialists after COVID-19 shut down much of the economy earlier this year and forced people to stay home.
Doctors and health care researchers say they expect telemedicine to play a greater role in health care once the pandemic finally fades, especially when it comes to remotely monitoring people with chronic conditions like hypertension or diabetes. That’s the speciality of Mountain View, California-based Livongo Health Inc.
The boards of both companies have approved the deal unanimously.
Once complete, Teledoc Health Inc. CEO Jason Gorevic will run the combined company, and Teledoc shareholders will own a 58% stake.
Before you consider Livongo Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Livongo Health wasn't on the list.
While Livongo Health currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
